Where Puma Biotechnology Stands With Analysts
Portfolio Pulse from Benzinga Insights
Puma Biotechnology (NASDAQ:PBYI) has received consistent 'Buy' ratings from analysts at HC Wainwright & Co. over the past three months, with a stable 12-month price target of $7.00. Despite facing revenue challenges and a high debt-to-equity ratio, the company shows strong net margin, ROE, and ROA compared to industry averages.
July 26, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Puma Biotechnology has received consistent 'Buy' ratings from HC Wainwright & Co. with a stable price target of $7.00. The company faces revenue challenges but shows strong net margin, ROE, and ROA.
The consistent 'Buy' ratings and stable price target suggest positive sentiment from analysts. Despite revenue challenges, the company's strong financial metrics (net margin, ROE, ROA) indicate effective management and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100